Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ZYNE

Zynerba Pharmaceuticals (ZYNE) Stock Price, News & Analysis

Zynerba Pharmaceuticals logo

About Zynerba Pharmaceuticals Stock (NASDAQ:ZYNE)

Advanced Chart

Key Stats

Today's Range
$1.30
$1.30
50-Day Range
$1.21
$1.39
52-Week Range
$0.25
$1.40
Volume
N/A
Average Volume
515,333 shs
Market Capitalization
$70.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ZYNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zynerba Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ZYNE Stock News Headlines

Harmony Biosciences: If It Ain't Broke
I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
US Penny Stocks To Watch In October 2024
Discover 3 US Penny Stocks With Market Caps Over $70M
See More Headlines

ZYNE Stock Analysis - Frequently Asked Questions

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) posted its quarterly earnings results on Monday, May, 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by $0.02.

Zynerba Pharmaceuticals (ZYNE) raised $42 million in an initial public offering on Wednesday, August 5th 2015. The company issued 3,000,000 shares at a price of $13.00-$15.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zynerba Pharmaceuticals investors own include Canopy Growth (CGC), Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Cronos Group (CRON), Meta Platforms (META) and Aurora Cannabis (ACB).

Company Calendar

Last Earnings
5/15/2023
Today
7/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ZYNE
CIK
1621443
Fax
N/A
Employees
25
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.80)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$35.04 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-90.03%
Return on Assets
-72.62%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.43
Quick Ratio
3.43

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.01 per share
Price / Book
1.29

Miscellaneous

Outstanding Shares
53,939,000
Free Float
46,905,000
Market Cap
$70.12 million
Optionable
Optionable
Beta
1.32

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:ZYNE) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners